Business Segments — Selling and other commercial expenses
Vertex Pharmaceuticals Business Segments — Selling and other commercial expenses decreased by 1.6% to $313.6M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 30.1%, from $241.1M to $313.6M. Over 3 years (FY 2022 to FY 2025), Business Segments — Selling and other commercial expenses shows an upward trend with a 33.0% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase relative to revenue may signal higher competition or the launch of new products requiring significant promotion.
Detailed definition
Operating costs related to marketing, sales force support, and commercial distribution of pharmaceutical products. This...
Peer comparison
Standardized as 'Selling, General, and Administrative' (SG&A) or 'Selling' expenses.
vrtx_segment_pharmaceuticals_selling_and_other_commercial_expensesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $117.23M | $117.23M | $117.23M | $117.23M | $148.1M | $148.1M | $148.1M | $148.1M | $191.7M | $196.3M | $216.9M | $233.6M | $241.1M | $264.6M | $278.3M | $318.8M | $313.6M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +26.3% | +0.0% | +0.0% | +0.0% | +29.4% | +2.4% | +10.5% | +7.7% | +3.2% | +9.7% | +5.2% | +14.6% | -1.6% |
| YoY Change | — | — | — | — | +26.3% | +26.3% | +26.3% | +26.3% | +29.4% | +32.5% | +46.5% | +57.7% | +25.8% | +34.8% | +28.3% | +36.5% | +30.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's business segments — selling and other commercial expenses?
- Vertex Pharmaceuticals (VRTX) reported business segments — selling and other commercial expenses of $313.6M in Q1 2026.
- How has Vertex Pharmaceuticals's business segments — selling and other commercial expenses changed year-over-year?
- Vertex Pharmaceuticals's business segments — selling and other commercial expenses increased by 30.1% year-over-year, from $241.1M to $313.6M.
- What is the long-term trend for Vertex Pharmaceuticals's business segments — selling and other commercial expenses?
- Over 3 years (2022 to 2025), Vertex Pharmaceuticals's business segments — selling and other commercial expenses has grown at a 33.0% compound annual growth rate (CAGR), from $468.9M to $1.1B.
- What does business segments — selling and other commercial expenses mean?
- Costs incurred to market and sell the company's drugs to healthcare providers and patients.